Roche Holding AG's R1658 Did Not Increase Blood Pressure According to Data; Good-Cholesterol Booster Looks Promising
Swiss pharmaceutical company Roche Holding AG said Tuesday that an experimental drug to raise the level of so-called good cholesterol was well tolerated in an intermediate study. Roche, based in Basel, said its cholesterol ester transfer protein, or CETP, inhibitor R1658 has been shown to be well tolerated either alone or in combination with statins and has a similar safety profile to placebo in its effect on blood pressure.